Abbott LaboratoriesvsEmbecta

ABT and EMBC stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$108.52

Value $189B

+1.18%
ABT's page

EMBC

Embecta Corp.

$6.46

Value $378M

+0.47%
EMBC's page

Abbott Laboratories (ABT) has a market value of $189B and Embecta (EMBC) $378M. Over the last year, with dividends, ABT moved -13.7% and EMBC -54.0%. The P/E is 40.1 for ABT and 4.3 for EMBC. Dividend yield: ABT 2.32%, EMBC 4.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$189B

    EMBC$378M

    ABT is 499 times EMBC

  • Revenue, 12 months

    ABT$48.2B

    EMBC$1.0B

    ABT is 47 times EMBC

  • Net income, 12 months

    ABT$4.7B

    EMBC$88M

    ABT is 54 times EMBC

  • Operating margin

    ABT13.8%

    EMBC21.9%

    8.1 points apart

  • ROIC

    ABT6.3%

    EMBC20.4%

    14.1 points apart

  • P/E

    ABT40.1

    EMBC4.3

    ABT is 9.3 times EMBC

  • Dividend yield

    ABT2.3%

    EMBC5.0%

    2.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT+20.7%

EMBC-51.1%

50100150202420252026
Returns by period
PeriodABTWith dividendsEMBCWith dividends
1 year since November 12, 2025-13.7%Price -15.8%-54.0%Price -55.4%
3 years since November 13, 2023+20.7%+6.5% a yearPrice +13.3%-51.1%-21.2% a yearPrice -56.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesEMBCEmbecta

Valuation

ABTEMBC
Valuation
Price$108.52$6.46
Market value$189B$378M
Enterprise value (EV)$215B$1.6B
P/E40.14.3
P/E, 5-year median33.79.6
P/B3.7–
EV/EBIT32.47.4
Free cash flow yield3.6%43.6%

Results and growth

ABTEMBC
Results and growth
Revenue, 12 months$48.2B$1.0B
Net income, 12 months$4.7B$88M
Free cash flow, 12 months$6.8B$165M
Earnings per share, 12 months$2.69$1.47
Revenue growth, year on year5.7%-3.8%
Revenue growth a year, past+5.1%over 5 years-0.1%over 5 years
EPS growth a year, past+8.3%over 5 years-26.4%over 5 years

Margins and returns on capital

ABTEMBC
Margins and returns on capital
Gross margin56.9%59.0%
Operating margin13.8%21.9%
Net margin9.8%8.6%
ROIC6.3%20.4%
ROE9.1%–

Balance sheet

ABTEMBC
Balance sheet
Cash$4.3B$215M
Total debt$31.2B$1.5B
Net debt / EBITDA3.34.8
Interest cover6.7×–

Dividends and buybacks

ABTEMBC
Dividends and buybacks
Dividend yield2.3%5.0%
Dividend per share, 12 months$2.52$0.32
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.8%5.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or EMBC

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Embecta?

By market value, Abbott Laboratories ($189B) is about 498.9 times Embecta ($378M), at today's prices.

How did ABT and EMBC stock do over the last 3 years?

Since November 13, 2023, ABT's price moved +13.3% and EMBC's -56.4%. With dividends: ABT +20.7% (+6.5% a year), EMBC -51.1% (-21.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or EMBC?

The dividend yield at today's price is 2.32% for Abbott Laboratories and 4.95% for Embecta. Over the last twelve months they paid $2.52 and $0.32 per share.

What is the P/E of ABT and EMBC?

At today's price, the P/E is 40.1 for ABT and 4.3 for EMBC. The median of the last five years was 33.7 and 9.6, which shows where each stands against its own past.

Which has the higher profit margins, Abbott Laboratories or Embecta?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 8.6% for Embecta, and the operating margin 13.8% and 21.9%. Revenue was $48.2B and $1.0B.

Which is the better investment, Abbott Laboratories or Embecta?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.